Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition
Xenetic Biosciences plans to acquire Santersus in an all-stock deal, forming Santersus Bio to tackle NET-driven diseases.
Share
Why It Matters
Xenetic Biosciences is buying another small company called Santersus. This deal means they can now work on more types of diseases, which shows they're trying to grow their business.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.